American Cancer Society

United in the Fight Against Colorectal Cancer

Retrieved on: 
Thursday, March 7, 2024
Breast cancer, Incidence, American Cancer Society, Woman, Amgen, ACS, CRC, Patient, Mortality, Colorectal cancer, Research, Exact sciences

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.

Key Points: 
  • A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.
  • Despite these escalating rates, there has been a lack of progress in developing effective treatment options for colorectal cancer patients, and persistent health disparities in incidence, mortality, and survivorship rates continue to exist.
  • United in Blue serves as a visual reminder for policymakers, emphasizing the necessity of increasing research funding for colorectal cancer and implementing a comprehensive plan to address the needs of the community.
  • Fight CRC’s United in Blue installation is sponsored by Amgen and Exact Sciences.

23andMe Launches New Genetic Reports on Common Forms of Cancer

Retrieved on: 
Wednesday, March 6, 2024
African Americans, SAN, Breast cancer, American Cancer Society, Cancer, Breast, 23andMe, Health, Genetics, Genomic Health, Database, PRS, Genetic, Patient, Black, Disease, Machine learning, Colorectal cancer, Premium, Research, Prostate cancer, Dietary supplement

The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.

Key Points: 
  • The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.
  • Availability of the breast cancer and prostate cancer PRS reports is based on self-reported birth sex.
  • The PRS models on which the new 23andMe reports are based were developed using the 23andMe database, and further validated using an external database.
  • To learn more about the new 23andMe PRS reports on cancer, and becoming a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

Beyond Meat® Unveils Its Beyond IV Platform, the Fourth Generation of the Beyond Burger® and Beyond Beef®, With Significant Advancements Across Taste, Health and Clean Label

Retrieved on: 
Wednesday, February 21, 2024
Collection, BYND, American Cancer Society, American Heart Association, Plant, Beyond Meat, BBQ, Meat, Health, American Heart, Nutrient, Pea, Beyond, Ecosystem, Taste, Sodium

EL SEGUNDO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, today announced the fourth generation of its core beef platform, Beyond IV, resulting in the unveiling of the company’s new Beyond Burger® and Beyond Beef® exclusively at retail. The new platform raises the bar for plant-based meat products and center-of-the-plate protein generally, and further cements Beyond Meat’s commitment to creating plant-based meat products that not only taste delicious but deliver important nutritional benefits.

Key Points: 
  • The extensive renovation focused on delivering goodness from plants – high-quality protein, good fats, fiber and key nutrients – in the company’s meatiest products yet.
  • Avocado oil is high in monounsaturated fats which the American Heart Association recommends as a heart-healthy choice2.
  • “Beyond IV represents a transformative step forward in delivering plant-based nutrition to the consumer in the form of meat.
  • The new Beyond Burger and Beyond Beef are expected to roll out exclusively at retailers across the U.S. this Spring.

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

Retrieved on: 
Thursday, March 7, 2024
Other Health, Managed Care, Oncology, General Health, Philanthropy, Medical Devices, Basketball, Sports, Foundation, Biotechnology, Science, Other Philanthropy, Other Science, Research, Health, Medical Supplies, Colorectal cancer, American Cancer Society, Multimedia, Hope, Death, Cancer, Black, Disease, Exact sciences

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball.
  • View the full release here: https://www.businesswire.com/news/home/20240307418330/en/
    Basketball great Jamal Mashburn is spreading the word about the importance of colorectal cancer screening beginning at age 45 with the "Box Out Colon Cancer" campaign.
  • (Photo: Business Wire)
    “Box Out Colon Cancer” is a direct response to the alarming, increasing rates of colon cancer diagnoses and deaths under the age of 50.3 With support from Mashburn, “Box Out Colon Cancer” is issuing a challenge to some of the nation’s leading college basketball coaches – over the age of 45 – asking them to get screened for colon cancer and encouraging others to do the same.
  • “Both with basketball and colon cancer, the best defense is a good offense,” says Mashburn, who took up the cause in loving memory of his mother, Helen, who battled colon cancer in her lifetime.

ATSG Surpasses $980,000 in Charitable Giving in 2023

Retrieved on: 
Wednesday, March 6, 2024
Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Other Transport, Fund Raising, Foundation, Air, Transport, Finance, Other Philanthropy, Environmental, Social and Governance (ESG), Logistics, Supply Chain Management, American Cancer Society, American Heart Association, Education, ATSG, Blood, Golf, Air Transport Services Group, Culture, Gold, United Way, Human, American Red Cross, Tot, Organization, Food security, Humanity, Pharmaceutical industry

Air Transport Services Group, Inc. (Nasdaq: ATSG) today announced that its charitable giving in 2023 topped $980,000, a fifteen percent increase over the prior year total.

Key Points: 
  • Air Transport Services Group, Inc. (Nasdaq: ATSG) today announced that its charitable giving in 2023 topped $980,000, a fifteen percent increase over the prior year total.
  • The company’s charitable giving in 2023 included:
    Over $308,000 raised through employee giving campaigns.
  • “At ATSG, we believe that giving back is an essential part of being a responsible corporate citizen,” said ATSG Chairman and CEO Joe Hete.
  • “Their enthusiasm for giving back is truly inspiring, and it is a testament to the strong culture of philanthropy that we have built at ATSG.”

City of Hope Launches First-of-its-Kind Mobile Cancer Prevention and Screening Program

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Health Technology, Other Health, American Cancer Society, Music, NCI, Multimedia, Education, Cancer, National Cancer Institute, AV, Volunteering, Risk, Death, Practitioner, Vaccine, Virus, Risk assessment, Nursing, Organization, Human resources, Policy, Genetic testing, Patient, Health equity, Research, Entertainment, Mobile phone

City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.
  • Cancer screening programs like City of Hope’s can help prevent thousands of additional cancer cases and deaths through early detection.
  • "Our comprehensive mobile cancer prevention and screening program is the next step in our mission to expand access to optimal cancer care, bringing our expertise outside the walls of our campus and into the communities we serve,” said Harlan Levine, president of Health Innovation and Policy at City of Hope.
  • While City of Hope’s mobile cancer prevention and screening program will initially launch in Southern California, the organization has plans to expand these offerings into additional communities of their other City of Hope cancer center locations.

Exchange Bank Announces Promotion of Jessica Hidalgo to Vice President, Regional Sales Manager

Retrieved on: 
Wednesday, February 21, 2024
Banking, Professional Services, Finance, Exchange, American Cancer Society, Multimedia, OTC, Bank, Exchange Bank, RSM, Casa Grande High School

Exchange Bank (OTC: EXSR) announces the promotion of Jessica Hidalgo from branch manager to regional sales manager of Exchange Bank’s north region.

Key Points: 
  • Exchange Bank (OTC: EXSR) announces the promotion of Jessica Hidalgo from branch manager to regional sales manager of Exchange Bank’s north region.
  • In her new role, Jessica will support the branch managers and their teams with financial growth goals, community involvement, team development and customer service.
  • After 11 years as an RSM, Jessica became a branch manager; first at the Cotati branch, then St. Francis, and most recently the Sonoma branch.
  • Over the years, Jessica has supported and volunteered for many nonprofit groups including the American Cancer Society, Redwood Empire Foodbank and COTS-Petaluma.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Retrieved on: 
Monday, February 19, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Metabolism, Immunotherapy, AstraZeneca, News, Daiichi Sankyo, National Cancer Institute, Lung cancer, Triple-negative breast cancer, Immunology, Patient, Cleavage, Biopharmaceutical, Social media, Progression-free survival, Treatment, BLA, Docetaxel, IHC, DXD, Pharmacotherapy, NSCLC, Breast cancer, Gefitinib, PD-1, Safety, Lung, Pemetrexed, PFS, American Cancer Society, Pircher, Observational study, MD, Sapporo Medical University, Food, Cancer, ADC, OS, Immunoglobulin G, Death, Medicine, Pharmaceutical industry

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Key Points: 
  • AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
  • In patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful PFS benefit and a numerically favorable OS trend.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

Olympus and the Colorectal Cancer Alliance Offer a Reminder About the Importance of Preventive Cancer Screenings

Retrieved on: 
Tuesday, March 5, 2024
Large intestine, PCP, Incidence, American Cancer Society, Woman, Texture, Gastroenterology, Colorectal cancer, Colonoscopy, TXI, Physician, Extrapyramidal system, ADR, Polyp, Colorectal Cancer Alliance, CRC, FIT, Learning, Risk, Adenoma, Health, History, USPSTF, Cancer, Patient, Diagnosis, CCA, Medical imaging

CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.

Key Points: 
  • CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.
  • More than 20 years ago, colorectal cancer (CRC) was known to be the fourth-leading cause of cancer death in men and women under the age of 50, according to the American Cancer Society.
  • Now, CRC is the leading cause of cancer death for men under the age of 50 and the second leading cause for women under 50.
  • Colorectal cancer is preventable, and the power to prevent it rests in your hands."

American Cancer Society Receives NBA Foundation Grant to Increase Underrepresented Students Entering Cancer Research Careers

Retrieved on: 
Friday, March 1, 2024
Engineering, Cancer, American Cancer Society, Research, Education, NBA, American Cancer Society Center, Female, Federation, Diversity, Face, SHE, History, Employment, Alaska Natives, Science, American Indians, National Institutes of Health, Nobel Prize, Student, Nursing

ATLANTA, March 1, 2024 /PRNewswire/ -- The American Cancer Society Center for Diversity in Cancer Research Training received an NBA Foundation grant to support programming for 300 underrepresented high school, college, and post-Baccalaureate students interested in oncology and cancer research in 21 NBA markets.

Key Points: 
  • ATLANTA, March 1, 2024 /PRNewswire/ -- The American Cancer Society Center for Diversity in Cancer Research Training received an NBA Foundation grant to support programming for 300 underrepresented high school, college, and post-Baccalaureate students interested in oncology and cancer research in 21 NBA markets.
  • An inclusive research community more effectively addresses cancer disparities, invigorates problem-solving, drives innovation, and accelerates the American Cancer Society's mission to improve the lives of people with cancer and their families.
  • "The NBA Foundation is honored to join them in this work through providing resources to enhance programming at the Center for Diversity in Cancer Research Training.
  • Racial and ethnic communities that bear a disproportionate burden of cancer continue to be underrepresented in the cancer research workforce.